Ethan Shen PhD - 09 Sep 2026 Form 4 Insider Report for YD Bio Ltd (YDES)

Reporting relationship: CEO, Director
Issuer ticker: YDES
Reported as of: 09 Sep 2026
Net transaction value: +$12,183
SEC form: 4
Accepted by SEC: 10 Sep 2026, 16:01:21 UTC
Prior SEC filing: 08 Sep 2026
Next SEC filing: 16 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Ethan Shen

Key filing fact

Ethan Shen PhD filed Form 4 for YD Bio Ltd (YDES) on 10 Sep 2026.

Key facts

This page summarizes Ethan Shen PhD's Form 4 filing for YD Bio Ltd (YDES).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Sep 2026, 16:01.

Change

Previous filing in this sequence was filed on 08 Sep 2026.
Current net transaction value: +$12,183.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002099921 Primary reporting owner

Shen Ethan PhD

Relationship: CEO, Director
Address: C/O YD BIO LIMITED, 12F., NO. 3, XINGNAN ST., NANGANG DIST., TAIPEI CITY, TAIWAN
Signature: /s/ Ethan Shen
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

YDES transaction

Ordinary Shares

Purchase

Transaction value: $12,183
Shares: +3,100
Change %: +0.03%
Price: $3.93
Shares after: 11,245,631
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F1

YDES holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 43,120,858
Date: 09 Sep 2026
Ownership: See Footnotes
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.80 to $4.09, inclusive. The reporting person undertakes to provide to YD Bio Ltd (the "Company"), any security holder of the Company or the staff of the U.S. Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of Ordinary Shares purchased at each separate price within the range set forth above.

Footnote F2

The reported shares are held by YD Biopharma Holding Limited, which is wholly owned by E820N Assets Ltd. (BVI), which is wholly owned by The E820N Trust (the "Trust"). Dr. Shen is the settlor, protector and sole beneficiary of the Trust, and is the beneficial owner of such shares.